Research Themes

Health economics of melanoma and kidney disease


PhD, MScMed(Clin Epi)(Hons)

Prof Rachael Morton

Director, Health Economics & Health Technology Assessment

Professor Rachael Morton is the Deputy Director at the CTC and also leads the Health Economics and Health Technology Assessment teams. She specialises in trial-based and modelled economic evaluation, patient reported outcome measures (PROMs) and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.


Research interests

  • Health economics of cancer and chronic diseases
  • Clinical trials
  • Health equity in disadvantaged populations both in Australia and overseas.
  • Patient reported outcome measures (PROMs)
  • Environmental impacts of healthcare
  • Measurement of quality of life and well-being


Teaching and supervision

Rachael coordinates short courses in health economics for government and industry and currently supervises five PhD candidates.



  • Within-trial and modelled economic evaluation
  • Preference elicitation
  • Outcomes assessment
  • Health equity
  • Chronic Kidney Disease
  • Melanoma and other cancers


Professional Associations

  • Board Director, Australian Clinical Trials Alliance (ACTA) member since 2016; Co-chair ACTA Reference Group – “Research Prioritisation: tools and criteria” since 2017
  • Past President, Health Services Research Association of Australia and New Zealand (HSRAANZ), member since 2011
  • Co-Convenor, Health Economists Alongside Trials (HEAT) special interest group with ACTA since 2020
  • Faculty Member, Melanoma Institute Australia, since 2017
  • Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Advisory Committee Member and Convenor, ANZDATA PROMs Working Group, since 2016
  • International Health Economics Association (IHEA) Program Chair 2018-2021, member since 2008
  • International Society for Pharmacoeconomic and Outcomes Research (ISPOR), member since 2009
  • Health Economists Study Group – UK (HESG) member since 2010
  • Cochrane Equity Methods Group member since 2013
  • Australia and New Zealand Society of Nephrology (ANZSN) member since 1996



View Rachael's publications.